Am J Psychiatry 158:1843-1849, November 2001
© 2001 American Psychiatric Association
Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C]DASB PET Imaging Study
Jeffrey H. Meyer, M.D., Ph.D.,
Alan A. Wilson, Ph.D.,
Nathalie Ginovart, Ph.D.,
Verdell Goulding, B.Sc.,
Doug Hussey, B.Sc.,
Karen Hood, M.Ed., and
Sylvain Houle, M.D., Ph.D.
OBJECTIVE: Selective serotonin reuptake inhibitors are commonly used to treat major depression; however, the percentage of serotonin (5-HT) transporter (5-HTT) sites occupied during clinical dosing is unknown. This study measured the proportion of 5-HTT sites blocked during paroxetine and citalopram treatment of depression and assessed the relationship between serum paroxetine levels and the proportion of 5-HTT sites blocked. METHOD: Twelve medication-free depressed patients completed a 6-week trial of either paroxetine (N=8) or citalopram (N=4). Striatal 5-HTT binding potential was measured with [11C]DASB and positron emission tomography, before and after 4 weeks of treatment. The binding potential is proportional to receptor density. Striatal 5-HTT binding potential was measured twice in six healthy subjects and once in 11 healthy subjects. RESULTS: A significant decrease in striatal 5-HTT binding potential was found after either treatment, compared to changes found over a 4-week period in healthy subjects. For patients treated with 20 mg/day of paroxetine (N=7), the mean proportion of 5-HTT sites occupied was 83%. For patients treated with 20 mg/day of citalopram (N=4), the mean 5-HTT occupancy was 77%. 5-HTT occupancy increased in a nonlinear relationship with serum levels of paroxetine such that a plateau of occupancy around 85% occurred for serum paroxetine levels greater than 28 µg/liter. CONCLUSIONS: During treatment with clinical doses of paroxetine or citalopram, approximately 80% of 5-HTT receptors are occupied. This change in 5-HTT binding potential is greater than the known physiological range of changes in 5-HTT binding potential but may be necessary for some therapeutic effects.
This article has been cited by other articles:
|
|
|
|
 
N. J. van der Wee, J. F. van Veen, H. Stevens, I. M. van Vliet, P. P. van Rijk, and H. G. Westenberg
Increased Serotonin and Dopamine Transporter Binding in Psychotropic Medication-Naive Patients with Generalized Social Anxiety Disorder Shown by 123I-{beta}-(4-Iodophenyl)-Tropane SPECT
J. Nucl. Med.,
May 1, 2008;
49(5):
757 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.-J. Chang, M. Guttman, and Y. Furukawa
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Brain,
January 1, 2008;
131(1):
120 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Wassink, H. C. Hazlett, E. A. Epping, S. Arndt, S. R. Dager, G. D. Schellenberg, G. Dawson, and J. Piven
Cerebral Cortical Gray Matter Overgrowth and Functional Variation of the Serotonin Transporter Gene in Autism
Arch Gen Psychiatry,
June 1, 2007;
64(6):
709 - 717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Parsey, A. Ojha, R. T. Ogden, K. Erlandsson, D. Kumar, M. Landgrebe, R. Van Heertum, and J. J. Mann
Metabolite Considerations in the In Vivo Quantification of Serotonin Transporters Using 11C-DASB and PET in Humans
J. Nucl. Med.,
November 1, 2006;
47(11):
1796 - 1802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Furey and W. C. Drevets
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1121 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Neumeister, X.-Z. Hu, D. A. Luckenbaugh, M. Schwarz, A. C. Nugent, O. Bonne, P. Herscovitch, D. Goldman, W. C. Drevets, and D. S. Charney
Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls.
Arch Gen Psychiatry,
September 1, 2006;
63(9):
978 - 986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Lotrich, R. R. Bies, G. S. Smith, and B. G. Pollock
Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies.
J Psychopharmacol,
July 1, 2006;
20(4 Suppl):
33 - 40.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. V. Parsey, R. S. Hastings, M. A. Oquendo, Y.-y. Huang, N. Simpson, J. Arcement, Y. Huang, R. T. Ogden, R. L. Van Heertum, V. Arango, et al.
Lower Serotonin Transporter Binding Potential in the Human Brain During Major Depressive Episodes
Am J Psychiatry,
January 1, 2006;
163(1):
52 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundberg, I. Odano, H. Olsson, C. Halldin, and L. Farde
Quantification of 11C-MADAM Binding to the Serotonin Transporter in the Human Brain
J. Nucl. Med.,
September 1, 2005;
46(9):
1505 - 1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Newberg, J. D. Amsterdam, N. Wintering, K. Ploessl, R. L. Swanson, J. Shults, and A. Alavi
123I-ADAM Binding to Serotonin Transporters in Patients with Major Depression and Healthy Controls: A Preliminary Study
J. Nucl. Med.,
June 1, 2005;
46(6):
973 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Axelson, J. M. Perel, B. Birmaher, G. Rudolph, S. Nuss, L. Yurasits, J. Bridge, and D. A. Brent
Platelet Serotonin Reuptake Inhibition and Response to SSRIs in Depressed Adolescents
Am J Psychiatry,
April 1, 2005;
162(4):
802 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. van der Wee, H. Stevens, J. A. Hardeman, R. C. Mandl, D. A. Denys, H. J. van Megen, R. S. Kahn, and H. M. Westenberg
Enhanced Dopamine Transporter Density in Psychotropic-Naive Patients With Obsessive-Compulsive Disorder Shown by [123I]{beta}-CIT SPECT
Am J Psychiatry,
December 1, 2004;
161(12):
2201 - 2206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Meyer, S. Houle, S. Sagrati, A. Carella, D. F. Hussey, N. Ginovart, V. Goulding, J. Kennedy, and A. A. Wilson
Brain Serotonin Transporter Binding Potential Measured With Carbon 11-Labeled DASB Positron Emission Tomography: Effects of Major Depressive Episodes and Severity of Dysfunctional Attitudes
Arch Gen Psychiatry,
December 1, 2004;
61(12):
1271 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Y. Fu, S. C. R. Williams, A. J. Cleare, M. J. Brammer, N. D. Walsh, J. Kim, C. M. Andrew, E. M. Pich, P. M. Williams, L. J. Reed, et al.
Attenuation of the Neural Response to Sad Faces in Major Depression by Antidepressant Treatment: A Prospective, Event-Related Functional Magnetic Resonance Imaging Study
Arch Gen Psychiatry,
September 1, 2004;
61(9):
877 - 889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Meyer, A. A. Wilson, S. Sagrati, D. Hussey, A. Carella, W. Z. Potter, N. Ginovart, E. P. Spencer, A. Cheok, and S. Houle
Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study
Am J Psychiatry,
May 1, 2004;
161(5):
826 - 835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Newberg, K. Plossl, P. D. Mozley, J. B. Stubbs, N. Wintering, M. Udeshi, A. Alavi, T. Kauppinen, and H. F. Kung
Biodistribution and Imaging with 123I-ADAM: A Serotonin Transporter Imaging Agent
J. Nucl. Med.,
May 1, 2004;
45(5):
834 - 841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Murphy, A. Lerner, G. Rudnick, and K.-P. Lesch
Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics
Mol. Interv.,
April 1, 2004;
4(2):
109 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Shiue, S.-R. Choi, P. Fang, C. Hou, P. D. Acton, C. Cardi, J. R. Saffer, J. H. Greenberg, J. S. Karp, H. F. Kung, et al.
N,N-Dimethyl-2-(2-Amino-4-18F-Fluorophenylthio)-Benzylamine (4-18F-ADAM): An Improved PET Radioligand for Serotonin Transporters
J. Nucl. Med.,
December 1, 2003;
44(12):
1890 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Grunder, A. Carlsson, and D. F. Wong
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Arch Gen Psychiatry,
October 1, 2003;
60(10):
974 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Suhara, A. Takano, Y. Sudo, T. Ichimiya, M. Inoue, F. Yasuno, Y. Ikoma, and Y. Okubo
High Levels of Serotonin Transporter Occupancy With Low-Dose Clomipramine in Comparative Occupancy Study With Fluvoxamine Using Positron Emission Tomography
Arch Gen Psychiatry,
April 1, 2003;
60(4):
386 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Szabo, U. D. McCann, A. A. Wilson, U. Scheffel, T. Owonikoko, W. B. Mathews, H. T. Ravert, J. Hilton, R. F. Dannals, and G. A. Ricaurte
Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions
J. Nucl. Med.,
May 1, 2002;
43(5):
678 - 692.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
